Abstract
The high incidence of multidrug-resistant (MDR) bacteria among patients admitted to ICUs has determined an increase of tigecycline (TGC) use for the treatment of severe infections. Many concerns have been raised about the efficacy of this molecule and increased dosages have been proposed. Our purpose is to investigate TGC safety and efficacy at higher than standard doses.
Lingua originale | English |
---|---|
pagine (da-a) | R90-R90 |
Numero di pagine | 9 |
Rivista | Critical Care |
Volume | 18 |
DOI | |
Stato di pubblicazione | Pubblicato - 2014 |
Keywords
- tygecicline